Experts discuss practical strategies for early recognition and coordinated care of tardive dyskinesia to enhance patient outcomes and quality of life.

Health care professionals discuss the risks of tardive dyskinesia in patients on dopamine receptor antagonists and emphasize the importance of education and monitoring.

In this episode, the panel focuses on how enhancing patient and clinician education can improve early recognition of tardive dyskinesia.

In this episode, the panel explains how structured assessments such as the Abnormal Involuntary Movement Scale are essential tools for identifying tardive dyskinesia and distinguishing it from other drug-induced movement disorders.

In this episode, panelists identify early recognition of tardive dyskinesia as a significant unmet need and describe key opportunities to improve screening.

In this episode, the panel discusses how clinicians determine whether treatment for tardive dyskinesia is warranted once abnormal movements are identified.

This episode outlines all treatment approaches available for tardive dyskinesia and how they are applied in practice.

In this episode, the panel explains how VMAT2 inhibitors became the foundation of modern tardive dyskinesia treatment.

In this episode, the panel reviews the efficacy and safety data supporting deutetrabenazine and valbenazine for tardive dyskinesia.

In this episode, the panel discusses key considerations for selecting and dosing VMAT2 inhibitors in tardive dyskinesia.

In this episode, the panel discusses how pharmacists and the broader care team can support adherence and strengthen communication when patients start deutetrabenazine or valbenazine.

In this episode, the panel reflects on how this program can help pharmacists strengthen their approach to tardive dyskinesia (TD) recognition and management.

In this closing episode, the panel outlines practical steps pharmacists can take to support ongoing tardive dyskinesia monitoring across the care continuum.